

# Lu Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/686013/publications.pdf>

Version: 2024-02-01

46  
papers

430  
citations

1039406

9  
h-index

839053

18  
g-index

48  
all docs

48  
docs citations

48  
times ranked

593  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of (6S)-cyclopropyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxamines as new HBV capsid assembly modulators. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 113974.	2.6	7
2	(âˆ“)âˆ“)-Lariciresinol Isolated from the Roots of <i>Isatis indigotica</i> Fortune ex Lindl. Inhibits Hepatitis B Virus by Regulating Viral Transcription. <i>Molecules</i> , 2022, 27, 3223.	1.7	6
3	Identification of dihydroquinolinone derivatives with cyclic ether moieties as new anti-HBV agents. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114518.	2.6	4
4	Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. <i>Lung Cancer</i> , 2021, 152, 39-48.	0.9	33
5	Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma. <i>Translational Oncology</i> , 2021, 14, 100942.	1.7	3
6	Generalized Haileyâ€“Hailey disease: Novel spliceâ€“site mutations of <i>ATP2C1</i> gene in Chinese population and a literature review. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2021, 9, e1580.	0.6	3
7	PML Suppresses Influenza Virus Replication by Promoting FBXW7 Expression. <i>Virologica Sinica</i> , 2021, 36, 1154-1164.	1.2	8
8	Skin Responses in Newly Diagnosed Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome After Therapy With Low-Dose Lenalidomide Plus Dexamethasone. <i>Frontiers in Immunology</i> , 2021, 12, 681360.	2.2	3
9	Skin-Colored Papules on the Right Lower Back of an Elderly Man. <i>JAMA Dermatology</i> , 2021, 157, 723.	2.0	0
10	Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status. <i>Annals of Translational Medicine</i> , 2021, 9, 937-937.	0.7	9
11	Cutaneous Vasculitis in Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2021, 157, 991.	2.0	1
12	Novel genetic characteristics in lowâ€“grade fetal adenocarcinoma of the lung. <i>Thoracic Cancer</i> , 2021, 12, 2789-2795.	0.8	5
13	The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	9
14	Inherited ichthyosis and fungal infection: an update on pathogenesis and treatment strategies. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 341-350.	0.4	5
15	Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib. <i>Pediatric Rheumatology</i> , 2021, 19, 1.	0.9	18
16	Possibility of brigatinibâ€“based therapy, or chemotherapy plus antiâ€“angiogenic treatment after resistance of osimertinib harboring <i>EGFR</i> T790Mâ€“cis/â€“797S mutations in lung adenocarcinoma patients. <i>Cancer Medicine</i> , 2021, 10, 8328-8337.	1.3	9
17	A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 756902.	1.3	0
18	Rapid remission with calcipotriol betamethasone in refractory Foxâ€“Fordyce disease. <i>Dermatologic Therapy</i> , 2020, 33, e13223.	0.8	0

#	ARTICLE	IF	CITATIONS
19	The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 63-69.	0.7	12
20	Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. <i>Thoracic Cancer</i> , 2020, 11, 3501-3509.	0.8	9
21	Real-world data on the effectiveness and safety of interferon-alpha-2a intralesional injection for the treatment of focally recalcitrant mycosis fungoides. <i>Annals of Translational Medicine</i> , 2020, 8, 920-920.	0.7	2
22	The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma. <i>Theranostics</i> , 2020, 10, 7635-7644.	4.6	5
23	Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study. <i>Lung Cancer</i> , 2020, 147, 229-236.	0.9	9
24	Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery. <i>Cancer Management and Research</i> , 2020, Volume 12, 12549-12556.	0.9	3
25	Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations. <i>Targeted Oncology</i> , 2020, 15, 357-364.	1.7	9
26	Amino acid prodrugs of NVR3-778: Design, synthesis and anti-HBV activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127103.	1.0	9
27	EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. <i>Lung Cancer</i> , 2020, 145, 186-194.	0.9	68
28	Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. <i>Cancer Medicine</i> , 2020, 9, 3328-3336.	1.3	16
29	Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China. <i>Thoracic Cancer</i> , 2020, 11, 679-685.	0.8	19
30	Antiviral activity of a polysaccharide from <i>Radix Isatidis</i> ( <i>Isatis indigotica</i> Fortune) against hepatitis B virus (HBV) in vitro via activation of JAK/STAT signal pathway. <i>Journal of Ethnopharmacology</i> , 2020, 257, 112782.	2.0	42
31	Identification of benzothiazones containing a hexahydropyrrolo[3,4-pyrrol moiety as antitubercular agents against MDR-MTB. <i>RSC Advances</i> , 2020, 10, 14410-14414.	1.7	6
32	Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study. <i>Cancer Medicine</i> , 2019, 8, 5823-5830.	1.3	9
33	Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance. <i>Thoracic Cancer</i> , 2019, 10, 1096-1102.	0.8	1
34	Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 9043-9043.	0.8	7
35	Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2019, 31, 349-356.	0.7	5
36	Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial. <i>Thoracic Cancer</i> , 2018, 9, 693-698.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety. <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 1-8.	2.6	31
38	Synthesis and Evolution of Berberine Derivatives as a New Class of Antiviral Agents against Enterovirus 71 through the MEK/ERK Pathway and Autophagy. <i>Molecules</i> , 2018, 23, 2084.	1.7	23
39	Survival in right-sided versus left-sided stage IB-IIIa non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e20509-e20509.	0.8	0
40	A real-world survival of subsequent therapy in ALK positive non-small cell lung cancer (NSCLC) patients with crizotinib resistance.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21093-e21093.	0.8	1
41	Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma. <i>Scientific Reports</i> , 2017, 7, 1453.	1.6	3
42	Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer. <i>Cancer Medicine</i> , 2016, 5, 2286-2293.	1.3	5
43	Impact of gender difference on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20064-e20064.	0.8	0
44	Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20008-e20008.	0.8	0
45	Tremellin, a Novel Symmetrical Compound, from the Basidiomycete <i>Tremella aurantialba</i> . <i>Helvetica Chimica Acta</i> , 2002, 85, 882.	1.0	7
46	Quality control of postoperative acute pain service. <i>Journal of Tongji Medical University</i> , 1999, 19, 310-313.	0.1	0